We are commited to patients living with blood cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

Our pipeline includes various targets and approaches in oncology today, from antibody-drug conjugates and small molecules to cell therapy-based approaches.

The result of this approach is a portfolio that includes many assets with complementary mechanisms of action and strong potential to span diverse tumor types and lines of therapy, both on their own and in combinations.

Encore presentation of Gilead and Kite-sponsored study at the EHA2024 Hybrid Congress in Madrid, Spain

We are commited to patients living with breast cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

We are commited to patients living with Thoracic cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.

We are commited to patients living with GU/GI/GYN cancer.
Explore ongoing trials, enrolling trials, and MoAs our trials are investigating.